Primary Care Focus Group

Medical Learning Institute Inc (MLI) is an independent non-profit provider of evidence-based continuing education designed to impact the practice behavior of the healthcare team leading to improve patient outcomes.

We’re seeking your expert clinical insights to help shape the future of continuing medical education in Alzheimer’s Disease and T2D Treatment in the form of Weekly Basal Insulin. Your feedback will directly influence the educational content we develop to support healthcare professionals like you.

Alzheimer's Disease Focus Group Survey

Name
Which of the following changes have you made in your practice after participating in this program (select all that apply)?
Research shows that ~1/3 (or 33%) of mild dementias are currently missed in the primary care setting. Do you think your practice is at, above, or below this value?
I find involving patients with mild cognitive impairment or mild Alzheimer’s disease and their caregivers in treatment decisions to generally be:
Have you discussed modifiable risk factors with your patients at risk for Alzheimer's disease this week?
What barriers have you experienced in assessing, diagnosing, and managing people with mild cognitive impairment and Alzheimer’s disease? (select all that apply)
How many of your patients have been impacted by changes you have made based on the activity?

Weekly Basal Insulin for T2D Focus Group Survey

Name
1. How confident are you in your ability to develop strategies for initiating, dosing, and titrating once-weekly basal insulin for T2D?
*Once commercially available. Weekly basal insulin formulations are not currently approved by the FDA.
4. Have you intensified basal insulin therapy earlier than you would in appropriate patients with T2D based on this activity?
6. Which of the following changes have you made in your practice after participating in this program? (select all that apply)
9. What are provider-level barriers that have the biggest impact as far as insulin underuse?
Select up to three; note there are no right or wrong answers.
10. Have you discussed novel basal insulins with your patients in the last week?
13. Have you identified people in your practice with T2D for whom you have (or plan to) recommend once-weekly basal insulin*?
*Once commercially available.
15. How many of your patients have been impacted by changes you have made based on the activity?
16. What are patient-level barriers associated with basal insulin?
Select up to three; note there are no right or wrong answers.
Once commercially available. Weekly basal insulin formulations are not currently approved by the FDA.

Signup for Free CME Opportunities

Signup for MLI’s mailing list to receive updates on our upcoming CME course launches

Facebook Twitter Linkedin Instagram Threads X-twitter
Subscribe to Mailing List
Scroll to Top